DeepMed Research

PACIRA PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase 4 Study in Adult Subjects Undergoing Posterior Lumbar Spine Surgeries

Phase 4

Terminated

Conditions: Postoperative Pain Management

Interventions: Drug: EXPAREL and Bupivacaine
Drug: Standard of Care

First Posted Date: 2019-04-25

Last Posted Date: 2021-11-09

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 65

Registration Number: NCT03927911

Locations: 🇺🇸
First Surgical Hospital, Bellaire, Texas, United States
🇺🇸
Marcus Neuroscience Institute, Boca Raton, Florida, United States
🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States

and more 9 locations

Evaluate the Iovera° Device in Treating Pain Associated With Anterior Cruciate Ligament Reconstruction

Not Applicable

Withdrawn

Conditions: ACL Reconstruction

Interventions: Device: iovera°

First Posted Date: 2019-04-10

Last Posted Date: 2019-05-10

Lead Sponsor: Pacira Pharmaceuticals, Inc

Registration Number: NCT03909516

Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section

Phase 4

Completed

Conditions: Elective Cesarean Section
Pain Management

Interventions: Drug: Exparel TAP + multi-modal pain regimen
Drug: 150 mcg Duramorph + multi-modal pain regimen
Drug: 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen

First Posted Date: 2019-02-26

Last Posted Date: 2022-07-18

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 167

Registration Number: NCT03853694

Locations: 🇺🇸
St. Peter's University Medical Center, New Brunswick, New Jersey, United States
🇺🇸
Thomas Jefferson Medical Center, Philadelphia, Pennsylvania, United States
🇺🇸
Columbia University Medical Center/NY Presbyterian Hospital, New York, New York, United States

and more 15 locations

Study to Evaluate the Efficacy and Safety of FX006 in Patients With Hip Osteoarthritis

Phase 3

Terminated

Conditions: Osteoarthritis, Hip

Interventions: Drug: FX006
Drug: Normal saline

First Posted Date: 2019-01-04

Last Posted Date: 2024-01-24

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 70

Registration Number: NCT03793010

Locations: 🇺🇸
National Pain Research Institute, Winter Park, Florida, United States
🇺🇸
Tampa Bay Medical Research, Clearwater, Florida, United States
🇺🇸
Artemis Institute for Clinical Research, San Diego, California, United States

and more 29 locations

Iovera° to Treat Pain Associated With ACL Reconstruction and Rehabilitation

Not Applicable

Withdrawn

Conditions: Anterior Cruciate Ligament Reconstruction

Interventions: Device: iovera°

First Posted Date: 2018-09-28

Last Posted Date: 2019-01-14

Lead Sponsor: Pacira Pharmaceuticals, Inc

Registration Number: NCT03688477

Locations: 🇺🇸
SurgiCare of Manhattan, New York, New York, United States

Multicenter Study for Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

Phase 3

Completed

Conditions: Postoperative Pain Management

Interventions: Drug: Exparel
Drug: 0.5% Bupivacaine HCl

First Posted Date: 2018-09-24

Last Posted Date: 2021-01-06

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 98

Registration Number: NCT03682302

Locations: 🇺🇸
Shriners Hospitals for Children-Chicago, Chicago, Illinois, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 14 locations

Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee

Phase 3

Completed

Conditions: Osteoarthritis, Knee

Interventions: Drug: FX006 32 mg

First Posted Date: 2018-05-18

Last Posted Date: 2024-01-24

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 129

Registration Number: NCT03529942

Locations: 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸
PMG Research, Inc. d/b/a PMG Research of Knoxville, Knoxville, Tennessee, United States
🇬🇧
University of Leeds, Leeds, United Kingdom

and more 7 locations

Study in Pediatric Subjects Evaluating Pharmacokinetics and Safety of EXPAREL

Phase 1

Completed

Conditions: Postoperative Pain Management

Interventions: Drug: Exparel

First Posted Date: 2018-04-02

Last Posted Date: 2023-08-02

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 15

Registration Number: NCT03485014

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

Study in Adult Subjects Undergoing Posterolateral Thoracotomy

Phase 1

Terminated

Conditions: Postoperative Pain Management

Interventions: Drug: EXPAREL

First Posted Date: 2018-02-12

Last Posted Date: 2019-02-06

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 5

Registration Number: NCT03428984

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip

Phase 2

Completed

Conditions: Osteoarthritis of the Shoulder
Osteoarthritis of the Hip

Interventions: Drug: TAcs 40 mg
Drug: FX006 32 mg

First Posted Date: 2017-12-22

Last Posted Date: 2024-01-24

Lead Sponsor: Pacira Pharmaceuticals, Inc

Target Recruit Count: 55

Registration Number: NCT03382262

Locations: 🇺🇸
Rochester Clinical Research, Rochester, New York, United States
🇺🇸
Biosolutions Clinical Research Center, La Mesa, California, United States
🇺🇸
TriWest Research Associates, LLC, El Cajon, California, United States

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy